TSHA250117C7500
- 0.05
- 0.000.00%
Taysha Gene Therapies Newsroom
Express News | Taysha Gene Therapies Files for Mixed Shelf Offering of up to $300 Mln - SEC Filing
Express News | Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
JMP Securities Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $5
Buy Rating for Taysha Gene Therapies Due to Safer Administration Method and Lower Viral Dose
Taysha Gene Therapies Analyst Ratings
Taysha Gene Therapies Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
CCORF Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Raises Target Price to $8
Taysha Gene Therapies Is Maintained at Buy by Chardan Capital
Taysha Gene Therapies Price Target Maintained With a $6.00/Share by Needham
Taysha Gene Therapies Shares Are Trading Higher. Cantor Fitzgerald Reiterated an Overweight Rating on the Stock.
Express News | Taysha Gene Therapies Shares Are Trading Higher. Cantor Fitzgerald Reiterated an Overweight Rating on the Stock
Cantor Fitzgerald Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $7
BMO Capital Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $5
Advance Auto Parts Posts Weak Results, Joins Harrow, Taysha Gene Therapies And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
A Quick Look at Today's Ratings for Taysha Gene Therapies(TSHA.US), With a Forecast Between $5 to $7.5
Why DLocal Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
Taysha Gene Therapies: Promising Developments and Strong Financial Position Support Buy Rating
Taysha Gene Therapies Advances in Rett Syndrome Trials
Taysha Gene Therapies, Inc. (TSHA) Q3 2024 Earnings Call Transcript Summary